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Aims Contrary to elderly patients with ischaemic-related acute heart failure (AHF) typically enrolled in North American and
European registries, patients enrolled in the sub-Saharan Africa Survey of Heart Failure (THESUS-HF) were middle-aged
with AHF due primarily to non-ischaemic causes. We sought to describe factors prognostic of re-admission and death in
this developing population.
Methods
and results
Prognostic models were developed from data collected on 1006 patients enrolled in THESUS-HF, a prospective registry
of AHF patients in 12 hospitals in nine sub-Saharan African countries, mostly in Nigeria, Uganda, and South Africa. The
main predictors of 60-day re-admission or death in a model excluding the geographic region were a history of malignancy
and severe lung disease, admission systolic blood pressure, heart rate and signs of congestion (rales), kidney function
(BUN), and echocardiographic ejection fraction. In a model including region, the Southern region had a higher risk.
Age and admission sodium levels were not prognostic. Predictors of 180-day mortality included malignancy, severe
lung disease, smoking history, systolic blood pressure, heart rate, and symptoms and signs of congestion (orthopnoea,
peripheral oedema and rales) at admission, kidney dysfunction (BUN), anaemia, and HIV positivity. Discrimination was
low for all models, similar to models for European and North American patients, suggesting that the main factors con-
tributing to adverse outcomes are still unknown.
Conclusion Despite the differences in age and disease characteristics, the main predictors for 6 months mortality and combined 60
days re-admission and death are largely similar in sub-Saharan Africa as in the rest of theworld, with some exceptions such
as the association of the HIV status with mortality.
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Introduction
Acute heart failure (AHF) is one of the most common reasons for ad-
mission tohospital, andamajordriver forhealth-relatedcost globally.
Its prevalence is shown to be high and outcomes dire in North
America,1 Europe,2 South America,3 Southeast Asia,4 and recently
also in sub-Saharan Africa.5
Despite the huge impact of this disease until recently little progress
has been made in characterizing the pathophysiology of the disease.
The 2012 European Society of Cardiology (ESC) guidelines on acute
andchronicheart failure6 highlight the lackof evidence-based therapy
for AHF compared with the therapeutic options for chronic heart
failure. Models examining predictors of outcomes such as short-term
re-admission and death have very low ability to discriminate between
those with and without the outcome with c-indexes ranging from 0.6
to 0.7,7– 9 where 0.5 represents chance and 1.0 perfect discrimin-
ation. This lack of understanding of pathophysiology and predictors
of outcome in AHF is at the core of the lack of progress in its treat-
ment with available therapies (diuretics and nitrates), such that out-
comes have been largely unchanged over the last 30–40 years.10
Acute heart failure exacts a heavy social and economic burden on
families and society in Africa. Contrary to North America and Europe
whereAHFaffects patients with an average ageof.70yearsold,1 the
THESUS-HF registry5 has shown that in sub-Saharan Africa the
disease affects men and women in the most productive years of life,
at an average age of 52.3 years and is mostly caused by hypertension
and not ischaemic heart disease. Hence, understanding the causes for
re-admission and death is especially important in this African popula-
tion and may be relevant to other developing regions of the world.
In this work, we identify patient characteristics associated with
60-day re-admission or death and 180-day mortality in a cohort of
1006 African patients admitted with AHF and enrolled in the
THESUS-HF registry.
Methods
Patients and data collected
THESUS-HF5 was a prospective, multicentre, international observational
survey conducted in 12 hospitals from 9 countries in the southern,
eastern, central, and western regions of sub-Saharan Africa. All patients
were recruited during an admission for AHF, mostly in Nigeria,
Uganda, and South Africa. Methods and results have been previously
described indetail.5 Inbrief, fromJuly2007 to June2010patients admitted
with dyspnoea and diagnosed with AHF based on symptoms and signs
(including dyspnoea, orthopnoea, dyspnoea on exercise, rales, oedema,
jugular venous pulse, and oxygen saturation) and who provided written
informed consent were enrolled into the study. The diagnosis was sup-
ported by echocardiographical findings and was confirmed by a cardiolo-
gist. Exclusion criteria included acute ST elevation myocardial infarction,
severe renal failure (patients on dialysis or creatinine .4 mg/dL), neph-
rotic syndrome, or hepatic failure. Approval was obtained fromthe ethics
committee of each participating institution and the study conformed to
the principles of the Declaration of Helsinki.
Detailed data collected at admission onto standardized case report
forms included medical history, medication use, laboratory values, and
physical examination with symptoms and signs of heart failure. Echocar-
diography and electrocardiography were also performed. Human im-
munodeficiency virus testing was performed as clinically indicated.
Patients were followed either by clinic visit or telephone contact
through 6 months for the occurrence of re-admissions and death. As
described in the main report, patients were classified as having either
an emerging or endemic cause of heart failure. Endemic causes included
rheumatic heart disease, cardiomyopathies, and infective causes, while
emerging causes included hypertension and ischaemic heart disease.
Statistical methods
Cox regression models were constructed considering the time from ad-
mission to the first event; times for patients without the event of interest
were censored at the earlier of the last date the patient was known to be
aliveor theperiodof interest. Prognosticmodelswereconstructed for the
two outcomes of interest considering candidate predictors chosen based
on data available in THESUS-HF, variables found to be predictive in other
AHF studies, and clinical judgment. Participating countries were grouped
into three regions: East which comprised Sudan (n ¼ 72), Ethiopia (n ¼
10), Kenya (n ¼ 32), and Uganda (n ¼ 154); West which comprised
Senegal (n ¼ 15), Nigeria (n ¼ 425), and Cameroon (n ¼ 90); and
South which comprised South Africa (n ¼ 132) and Mozambique (n ¼
76). Because region was found to be significantly associated with re-
admission or death, and because regional cultural and medical practice
patterns might affect admission, we also constructed a model examining
only patient clinical characteristics.
The linearity of association between each continuous predictor and
each outcome was assessed using restricted cubic splines with four
‘knots’ with a test of the significance of the non-linear terms.11 Where
the association was non-linear, a readily interpreted transformation
was chosen through examination of plots of the predicted log hazard
ratio against the value of the predictor and changes in Akaike’s informa-
tion criterion. If little information was lost, the same transformation was
used tomodel bothoutcomes. Multiple imputation assumingmultivariate
normality (SAS PROC MI) was used to handle missing values. The imput-
ation model included all covariates under consideration for the multivari-
able models. The ranges of imputed values were restricted to the ranges
of the observed values. Seven imputation data sets were used. Parameter
estimates were averaged across these data sets using Rubin’s algorithm12
(SAS PROC MIANALYZE). SAS version 9.2 (SAS Institute, Inc, Cary, NC,
USA) was used for the analyses.
We constructed a multivariable model for each of the outcomes from
the candidate predictors listed in Table 1 (except those effects that were
dropped), with continuous variables included using the model forms indi-
cated in Tables 2–4. For the 60-day composite endpoint, one model was
assessed with the inclusion of region as a predictor and one excluding
region. Backwards selection was performed in each of the imputed
data sets, with the criterion for staying at P ¼ 0.10. Predictors that
were significant in at least four of the imputed data sets were kept in
the reduced model. The discrimination of the models was evaluated
using the c-index.13 The model fit was assessed visually using calibration
plots11 which were generated from the stacked imputation data sets.14 In
these plots, patients were grouped by deciles of predicted risk, and the
mean predicted risk for each group was compared with the Kaplan–
Meier estimate of risk in these same groups.
Results
Of the 1006 patients included in the THESUS-HF database, one
patient was excluded who had unreasonable data pertaining to
both outcomes (i.e. subject had a date of death listed before admis-
sion) giving 1005 patients for this analysis. Of the 1006 patients en-
rolled 430 were enrolled in Nigeria, 154 in Uganda and 132 in
South Africa. Patients were followed a median of 180 days.
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Ninety-five patients died and 74 were readmitted through 60 days;
138 patients experienced a death or re-admission through 60 days,
where the first event was re-admission for 74 patients and death
for 64 patients. A total of 151 patients died through 180 days after ad-
mission. A total of 38 candidate predictors were considered. The dis-
tribution and proportion of unavailable values for each predictor are
given in Table 1. A total of 522 (51.9%) patients were missing at least
one candidate variable when cholesterol was not included as a pre-
dictor; onevariablewasmissing for284 patients, two for 162patients,
three for 72 patients, and four or more for 140 patients. We also con-
sidered cholesterol as a predictor, although it is measured only when
clinically indicated in African patients with AHF. With the inclusion of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Candidate predictors for re-admission and death
Variable N n Distribution (%) for
dichotomous; 25th %ile, median,
75th %ile for continuous
%missing Comments
Hx of DM 1004 114 (11.4) 0.2
Hx of IHD 1004 82 (8.2) 0.2
Valvular disease 1000 272 (27.2) 0.6
HIV positive 992 65 (6.6) 1.4
Hypertension 1002 556 (55.5) 0.4
Hyperlipidaemia 981 90 (9.2) 2.5
HX of stroke 1005 25 (2.5) 0.1
HX of PVD 1003 12 (1.2) 0.3
Current or former smoker 1002 98 (9.8) 0.4
Malignancy 1003 13 (1.3) 0.3
Hx of depression 1004 33 (3.3) 0.2
Hx of dementia 1004 22 (2.2) 0.2
Hx of atrial fibrillation 998 184 (18.4) 0.8
Hx of pericardial Disease 1000 53 (5.3) 0.6
Hx of Cardiomyopathy 994 416 (41.8) 1.2
Hx of cor pulmonale 995 72 (7.2) 1.1
Age, years 996 39, 55, 67 1.0
Male sex 1005 494 (49.2) 0.1
White race 999 15 (1.5) 0.7 Dropped from consideration as
there were no events for either
outcome in 15 white subjects
Ejection fraction, % 930 27, 38, 50 7.6
BMI, kg/m2 968 20.9, 24.0, 28.0 3.8 Extreme values of 214.5 and 121.4 set
to missing for analysis
BUN, mg/dL 971 16.5, 26.6, 42.0 3.5 Values ,6 set to missing
Creatinine, mg/dL 970 0.89, 1.12, 1.5 3.6 Values ,0.4 set to missing
Glucose, mg/dL 878 84.0, 93.7, 117.0 12.7
Haemoglobin, g/dL 967 10.7, 12.3, 13.7 3.9
Lymphocytes, % 839 20.0, 30.0, 39.6 16.6
Sodium, mmol/L 946 131.0, 135.8, 139.1 6.0
Cholesterol, mg/dL 649 124.0, 152.1, 187.0 35.5 Not measured in large proportion
of study population
Total WBC, /mm3 or /cumm or/mL or /mcL 963 5200, 6800, 8980 4.3
Systolic BP, mmHg 994 106, 126.5, 150 1.2
Diastolic BP, mmHg 992 70, 80, 100 1.4 Collinear with systolic BP.
Dropped from consideration
Heart rate, b.p.m. 997 90, 104, 116 0.9
Respiration, breaths/min 989 26, 29, 34 1.7
Orthopnoea, (0/1 vs. 2/3) 838 741 (88.4) 16.7
Peripheral oedema, (0/1 vs. 2/3) 990 665 (67.2) 1.6
Rales, (0/1 vs. 2/3) 880 565 (64.2) 12.5
lifestyle (emerging ¼ 1, endemic ¼ 0) 980 507 (51.7) 2.6
Region 1006 East: 268, South: 208, West: 530 0
Predictors and outcomes in sub-Saharan African patients with acute heart failure 3153
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cholesterol 646 (64.3%) of the patients were missing a value for at
least one predictor. Models were run for each outcome including
and excluding cholesterol as a predictor. Despite the high number
of patients with unavailable baseline cholesterol, the variables that
stayed in the model for the outcomes were the same whether or
not cholesterol was included.
Univariable associations with the composite outcome, and the
final multivariable models with and without consideration of the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Models for all-cause death or re-admission through 60 days
Predictor HR for a change of Univariable models Multivariable model
Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value
Hx of DM Yes/no 1.29 (0.81, 2.08) 0.2862
Hx of IHD Yes/no 1.00 (0.55, 1.81) 0.9948
Valvular disease Yes/no 1.04 (0.72, 1.52) 0.8275
HIV positive Yes/no 1.57 (0.88, 2.80) 0.1241
Hypertension Yes/no 0.86 (0.62, 1.20) 0.3756
Hyperlipidaemia Yes/no 0.40 (0.17, 0.95) 0.0373 0.47 (0.20, 1.12) 0.0891
HX of stroke Yes/no 0.27 (0.04, 1.98) 0.1984
HX of PVD Yes/no 1.13 (0.27, 4.66) 0.8644
Current or former smoker Yes/no 0.76 (0.41, 1.43) 0.3995
Malignancy Yes/no 5.07 (2.25, 11.45 ,0.0001 5.04 (2.19, 11.56) 0.0001
Hx of depression Yes/no 1.21 (0.49, 2.97) 0.6831
Hx of dementia Yes/no 0.92 (0.29, 2.92) 0.8933
Hx of atrial Fibrillation Yes/no 1.34 (0.90, 1.99) 0.1509
Hx of pericardial disease Yes/no 1.29 (0.67, 2.47) 0.4423
Hx of cardiomyopathy Yes/no 0.96 (0.68, 1.35) 0.8133
Hx of cor plmonale Yes/no 2.50 (1.57, 4.00) 0.0001 1.75 (1.07, 2.87) 0.0268
Age, years 10 0.95 (0.87, 1.04) 0.2443
Male Sex Yes/no 1.16 (0.83, 1.63) 0.3756
Ejection fraction, %a 50 vs. 27 0.94 (0.73, 1.21) 0.0523 0.89 (0.79, 1.14) 0.1355
BMI, kg/m2 5 1.04 (0.90, 1.20) 0.6127
BUN, mg/dLa Doubling 1.39 (1.18, 1.63) ,0.0001 1.46 (1.23, 1.73) ,0.0001
Creatinine, mg/dLa 1.55 vs. 0.90 1.40 (1.07, 1.83) 0.0095
Glucose, mg/dL 10 0.99 (0.95, 1.03) 0.5489
Haemoglobin, g/dL 1 0.92 (0.86, 0.99) 0.0238
Lymphocytes, % 5 0.96 (0.90, 1.03) 0.2275
Sodium, mmol/L 5 0.87 (0.77, 0.98) 0.0263
Total WBC, /mm3 or /cumm or /mL or /mcLa Doubling 1.10 (0.84, 1.43) 0.4833
Cholesterol, mg/dL 10 0.98 (0.94, 1.02) 0.2423
Systolic BP, mmHg 10 0.91 (0.86, 0.96) 0.0009 0.91 (0.86, 0.97) 0.0017
Heart rate, b.p.m. 5 1.04 (1.00, 1.08) 0.0300
Respiration, breaths/min 5 1.07 (0.97, 1.18) 0.1836
Orthopnoeab (2/3 vs. 0/1) 1.78 (0.89, 3.56) 0.1033
Peripheral oedemac (2/3 vs. 0/1) 1.60 (1.08, 2.37) 0.0194
Ralesd (2/3 vs. 0/1) 2.16 (1.38, 3.38) 0.0008 2.18 (1.36, 3.50) 0.0012
Heart failure causee (emerging ¼ 1, endemic ¼ 0) 0.78 (0.56, 1.09) 0.1497
Region (South vs. West) 1.32 (0.89, 1.94) 0.0141 1.83 (1.21, 2.78) 0.0025
Region (East vs. West) 0.62 (0.39, 0.97) 0.78 (0.48, 1.27)
C-statistic (95% confidence interval) 0.6986 (0.6521–0.7451)
aAppropriate transformation used due to the non-linear relationship between predictor and outcome.
bOrthopnoea defined as: 0 ¼ none, +1 ¼ 1 pillow (10 cm), +2 ¼ 2 pillow (20 cm), +3 ¼ 3 pillow (.30 cm).
cPeripheral oedema defined as: 0, complete absence of skin indentation with mild digital pressure in all dependent areas; 1+, indentation of skin that resolves over 10–15 s; 2+,
identation of skin is easily created with limited pressure and disappears slowly (15–30 s or more); 3+, large areas of indentation easily produced and slow to resolve (.30 s).
dRales defined as: 0, no rales after clearing with cough; 1, moist or dry rales heard in lowerone-third of 1 or both lung fields that persist after cough; 2, moist or dry rales heard
throughout the lower half to two-thirds of 1 or both lung fields; 3, moist or dry rales heard throughout both lung fields.
eEndemic causes included rheumatic heart disease, cardiomyopathies, and infective causes, while emerging causes included hypertension and ischaemic heart disease.
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geographic region are given in Tables 2 and 3, respectively. Adjusted
for geographic region malignancy, cor pulmonale, higher admission
BUN level, and presence of rales were found to significantly increase
the risk of death or re-admission within 60 days, while hyperlipid-
aemia, and higher systolic blood pressure reduced the risk
(Table 2). Unlike for other continuous predictors, the association
of ejection fraction with the log hazard ratio was non-linear, with
risk increasing for patients with ejection fraction both less than and
greater than 40%. Patients enrolled in Southern centres were at
higher risk of the composite outcome, while those enrolled in
Eastern centres were at lower risk, compared with those enrolled
in Western centres. Considering region, the c-index for the
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Models for all-cause death or re-admission through 60 days, excluding region
Predictor HR for a change of Univariable models Multivariable model
Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value
Hx of DM Yes/no 1.29 (0.81, 2.08) 0.2862
Hx of IHD Yes/no 1.00 (0.55, 1.81) 0.9948
Valvular disease Yes/no 1.04 (0.72, 1.52) 0.8275
HIV positive Yes/no 1.57 (0.88, 2.80) 0.1241
Hypertension Yes/no 0.86 (0.62, 1.20) 0.3756
Hyperlipidaemia Yes/no 0.40 (0.17, 0.95) 0.0373 0.49 (0.21, 1.19) 0.1156
HX of stroke Yes/no 0.27 (0.04, 1.98) 0.1984
HX of PVD Yes/no 1.13 (0.27, 4.66) 0.8644
Current or former smoker Yes/no 0.76 (0.41, 1.43) 0.3995
Malignancy Yes/no 5.07 (2.25, 11.45) ,0.0001 4.31 (1.89, 9.82) 0.0005
Hx of depression Yes/no 1.21 (0.49, 2.97) 0.6831
Hx of dementia Yes/no 0.92 (0.29, 2.92) 0.8933
Hx of atrial Fibrillation Yes/no 1.34 (0.90, 1.99) 0.1509
Hx of pericardial disease Yes/no 1.29 (0.67, 2.47) 0.4423
Hx of cardiomyopathy Yes/no 0.96 (0.68, 1.35) 0.8133
Hx of cor pulmonale Yes/no 2.50 (1.57, 4.00) 0.0001 2.03 (1.24, 3.32) 0.0048
Age, years 10 0.95 (0.87, 1.04) 0.2443
Male sex Yes/no 1.16 (0.83, 1.63) 0.3756
Ejection fraction, %a 50 vs. 27 0.94 (0.73, 1.21) 0.0523 0.97 (0.75, 1.26) 0.0981
BMI, kg/m2 5 1.04 (0.90, 1.20) 0.6127
BUN, mg/dLa Doubling 1.39 (1.18, 1.63) ,0.0001 1.42 (1.19, 1.68) ,0.0001
Creatinine, mg/dLa 1.55 vs. 0.90 1.40 (1.07, 1.83) 0.0095
Glucose, mg/dL 10 0.99 (0.95, 1.03) 0.5489
Haemoglobin, g/dL 1 0.92 (0.86, 0.99) 0.0238
Lymphocytes, % 5 0.96 (0.90, 1.03) 0.2275
Sodium, mmol/L 5 0.87 (0.77, 0.98) 0.0263
Total WBC, /mm3 or /cumm or /mL or /mcLa Doubling 1.10 (0.84, 1.43) 0.4833
Cholesterol, mg/dL 10 0.98 (0.94, 1.02) 0.2423
Systolic BP, mmHg 10 0.91 (0.86, 0.96) 0.0009 0.92 (0.87, 0.98) 0.0048
Heart rate, b.p.m. 5 1.04 (1.00, 1.08) 0.0300 1.04 (1.00, 1.08) 0.0723
Respiration, breaths/min 5 1.07 (0.97, 1.18) 0.1836
Orthopnoeab (2/3 vs. 0/1) 1.78 (0.89, 3.56) 0.1033
Peripheral oedemac (2/3 vs. 0/1) 1.60 (1.08, 2.37) 0.0194
Ralesd (2/3 vs. 0/1) 2.16 (1.38, 3.38) 0.0008 2.04 (1.31, 3.16) 0.0016
Heart failure causee (emerging ¼ 1, endemic ¼ 0) 0.78 (0.56, 1.09) 0.1497
C-statistic (95% confidence interval) 0. 6826 (0.6375–0.7294)
aAppropriate transformation used due to the non-linear relationship between predictor and outcome.
bOrthopnoea defined as: 0 ¼ none, +1 ¼ 1 pillow (10 cm), +2 ¼ 2 pillow (20 cm), +3 ¼ 3 pillow (.30 cm).
cPeripheral oedema defined as: 0, complete absence of skin indentation with mild digital pressure in all dependent areas; 1+, indentation of skin that resolves over 10–15 s; 2+,
indentation of skin is easily created with limited pressure and disappears slowly (15–30 s or more); 3+, large areas of indentation easily produced and slow to resolve (.30 s).
dRales defined as: 0, no rales after clearing with cough; 1, moist or dry rales heard in lowerone-third of 1 or both lung fields that persist after cough; 2, moist or dry rales heard
throughout the lower half to two-thirds of 1 or both lung fields; 3, moist or dry rales heard throughout both lung fields.
eEndemic causes included rheumatic heart disease, cardiomyopathies, and infective causes, while emerging causes included hypertension and ischaemic heart disease.
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multivariable model was 0.70, indicating a moderate degree of dis-
crimination (Table 2). The same multivariable predictors were
obtained when region was not considered, except that heart rate
also entered the model (Table 3). The C-index for this multivariable
model (0.68) was slightly less than for that including region.
Univariable associations and the multivariable model of death
through 180 days are given in Table 4. Known HIV positivity, malig-
nancy, cor pulmonale, male sex, lower haemoglobin, lower systolic
blood pressure, and presence of orthopnoea, peripheral oedema,
and rales were found to increase risk, while current or former
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Models for all-cause death through 180 days
Predictor HR for a change of Univariable models Multivariable model
Hazard ratio
(95% CI)
P-value Hazard ratio
(95% CI)
P-value
Hx of DM Yes/no 1.25 (0.80, 1.97) 0.3260
Hx of IHD Yes/no 0.56 (0.27, 1.15) 0.1121
Valvular disease Yes/no 1.05 (0.73, 1.51) 0.7882
HIV positive Yes/no 1.98 (1.20, 3.29) 0.0081 1.62 (0.94, 2.78) 0.0805
Hypertension Yes/no 0.76 (0.55, 1.04) 0.0859
Hyperlipidaemia Yes/no 0.43 (0.20, 0.96) 0.0382
HX of stroke Yes/no 0.77 (0.24, 2.43) 0.6544
HX of PVD Yes/no 0.92 (0.22, 3.79) 0.9074
Current or former smoker Yes/no 0.57 (0.29, 1.12) 0.1050 0.51 (0.25, 1.03) 0.0592
Malignancy Yes/no 4.26 (1.76, 10.33) 0.0014 3.00 (1.22, 7.35) 0.0166
Hx of depression Yes/no 1.16 (0.47, 2.85) 0.7474
Hx of dementia Yes/no 1.48 (0.61, 3.63) 0.3883
Hx of atrial fibrillation Yes/no 1.17 (0.79, 1.74) 0.4371
Hx of pericardial disease Yes/no 0.89 (0.43, 1.81) 0.7384
Hx of cardiomyopathy Yes/no 1.18 (0.86, 1.63) 0.3060
Hx of Cor pulmonale Yes/no 2.14 (1.33, 3.44) 0.0017 1.99 (1.22, 3.24) 0.0057
Age, years 10 0.93 (0.85, 1.01) 0.0845
Male sex Yes/no 1.08 (0.78, 1.49) 0.6409 1.38 (0.97, 1.96) 0.0699
Ejection fraction, % 5 0.96 (0.92, 1.02) 0.1657
BMI, kg/m2 5 1.01 (0.88, 1.16) 0.9101
BUN, mg/dLa Doubling 1.27 (1.08, 1.50) 0.0033
Creatinine, mg/dLa 1.55 vs. 0.90 1.37 (1.14, 1.65) 0.0020 1.36 (1.12, 1.64) 0.0051
Glucose, mg/dL 10 0.98 (0.95, 1.02) 0.3820
Haemoglobin, g/dL 1 0.91 (0.85, 0.97) 0.0050 0.93 (0.87, 1.00) 0.0488
Lymphocytes, % 5 1.00 (0.93, 1.07) 0.9657
Sodium, mmol/L 5 0.87 (0.78, 0.99) 0.0294
Cholesterol, mg/dL 10 0.95 (0.91, 0.99) 0.0282
Total WBC, /mm3 or /cumm or /mL or /mcLa Doubling 1.14 (0.89, 1.46) 0.3060
Systolic BP, mmHg 10 0.86 (0.81, 0.91) ,0.0001 0.86 (0.81, 0.91) ,0.0001
Heart rate, b.p.m.a 116 vs. 90 1.29 (0.99, 1.67) 0.0165 1.34 (1.01, 1.81) 0.0845
Respiration, breaths/min 5 1.02 (0.93, 1.13) 0.6641
Orthopnoeab (2/3 vs. 0/1) 2.69 (1.30, 5.56) 0.0079 1.86 (0.85, 4.08) 0.1194
Peripheral oedemac (2/3 vs. 0/1) 2.26 (1.50, 3.40) ,0.0001 1.91 (1.23, 2.97) 0.0043
Ralesd (2/3 vs. 0/1) 2.11 (1.41, 3.18) 0.0003 1.60 (1.03, 2.50) 0.0380
Heart failure causee (emerging ¼ 1, endemic ¼ 0) 0.72 (0.52, 0.99) 0.0431
Region (South vs. West) 1.21 (0.84, 1.76) 0.0042
Region (East vs. West) 0.53 (0.34, 0.83)
C-statistic (95% confidence interval) 0.7231 (0.6849–0.7451)
aAppropriate transformation used due to the non-linear relationship between predictor and outcome.
bOrthopnoea defined as: 0 ¼ none, +1 ¼ 1 pillow (10 cm), +2 ¼ 2 pillow (20 cm), +3 ¼ 3 pillow (.30 cm).
cPeripheral oedema defined as: 0, complete absence of skin indentation with mild digital pressure in all dependent areas; 1+, indentation of skin that resolves over 10–15 s; 2+,
indentation of skin is easily created with limited pressure and disappears slowly (15–30 s or more); 3+, large areas of indentation easily produced and slow to resolve (.30 s).
dRales defined as: 0, no rales after clearing with cough; 1, moist or dry rales heard in lowerone-third of 1 or both lung fields that persist after cough; 2, moist or dry rales heard
throughout the lower half to two-thirds of 1 or both lung fields; 3, moist or dry rales heard throughout both lung fields.
eEndemic causes included rheumatic heart disease, cardiomyopathies, and infective causes, while emerging causes included hypertension and ischaemic heart disease.
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smoking reduced risk (Table 4). The associations of creatinine and
heart rate with the log hazard ratio for mortality were non-linear
(Figure1). Patients with a higher heart ratewere generally at increased
risk; while the model-predicted risk appears to fall again, this is likely
because of undue influence of a fewpatients with extreme heart rates
(six patients with HR .170 b.p.m.). The model-predicted associ-
ation with creatinine was an apparent inverted U shape with patients
with creatinine levels of 1.9 mg/dL at highest risk; risks appear to
decrease with values .4 mg/dL; however, very few (32) patients
had these extreme values. The C-index for the multivariable model
was 0.72.
Calibration plots, comparing observed event rates with those pre-
dicted by the models, are given in Figure 2 for death or re-admission
through Day 60 (with, Figure 2A, and without, Figure 2B consideration
of region) and in Figure 3 for mortality through Day 180. Risks pre-
dicted by the models were generally close to those observed
among patients grouped by deciles of predicted risk.
Discussion
The current manuscript is an analysis of the THESUS registry.5 As
previously noted the main finding of the THESUS registry points to
the fact that patients who present with AHF in sub-Saharan Africa
are younger, less have ischaemic heart disease or risk factors for is-
chaemic heart disease (such as smoking) and many more have valvu-
lar (mostly rheumatic) heart disease and are hypertensive. As has
been found in other studies,7– 9 the main predictors of either re-
admission or death in the model that excludes region (Table 3) are
a history of malignancy and severe lung disease, admission systolic
blood pressure, heart rate and signs of congestion (rales), kidney
function (BUN), and echocardiographic ejection fraction. In the
model in which region has been included (Table 2), the Southern
African region seems to confer a higher risk of re-admission suggest-
ing that cultural and health economics-related factors may contribute
to the decision to re-admit a patient after an AHF event, as opposed
to outpatient clinic treatment. Interestingly, some factors that rou-
tinely contribute to similar models in North America and Europe
have a lesser role in sub-Saharan Africa. These should be confirmed
in further studies in potentially larger number of patients and more
hospitals. Most notably age and sodium levels at admission may
have potentially less of a predictive effect in sub-Saharan Africa.
Age may have a lesser role in this population because these patients
are almost 20 years younger on average than AHF patients in North
American and European registries. Sodium may play a lesser role
Figure 1 Non-linear associations of continuous predictors with all-cause death through 180 days.
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since most patients are young and the most common cause of heart
failure is hypertension which may be associated with less neurohor-
monal activation than end-stage ischaemic cardiomyopathies which
are more prevalent in North America and Europe, especially
among the sickest AHF patients who are more commonly
re-admitted after discharge.
The main predictors of 180-day mortality include malignancy,
severe lung disease, smoking history, systolic blood pressure, heart
rate, and symptoms and signs of congestion (orthopnoea, peripheral
oedema, and rales) at admission, kidney dysfunction (BUN), anaemia,
and being HIV positive. Again, many of these predictors are the same
as those reported in similar studies in North America and Europe, al-
though some notable differences are apparent. Again, the interpret-
ation of these differences should be tempered by the fact that the
study is relatively small and was recruited in a selected group of hos-
pitals, mostly advance medical centres in each country. The role of
HIV positivity as a predictor of adverse outcome is important.
Sodium was not found to be a predictor of mortality in the current
study (as is the case of re-admission and death), suggesting again
that neurohormonal activation involving the renin–angiotensin
system may have a lesser role in the HF process in sub-Saharan
Africa, a finding in line with the reduced efficacy of ACEi in African
Americans,15 suggesting that other therapies such as combination
of hydralazine and nitrates should be further explored in this popula-
tion. Finally, the association of smoking with less adverse outcome
may relate to the diagnosis of AHF being wrong and the breathless-
ness was due to lung disease, and this misdiagnosis led to the asso-
ciated cigarette smoking being seen as conferring survival advantage.
Similar to other studies in which short-term re-admission and
death and intermediate-term mortality were modelled in AHF the
strength of the predictive models are modest with C-indexes in the
range of 0.68–0.72. These C-indexes suggest that although some of
the variability in outcomes can be explained by the factors examined,
Figure2 (A) Calibration plot for multivariable model for all-cause death or re-admission through 60 days. Model including region. (B) Calibration
plot for multivariable model for all-cause death or re-admission through 60 days. Model excluding region.
Figure 3 Calibration plot for multivariable model for all-cause
death through Day 180.
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other causes for re-admission and death after an AHF are still
unknown in sub-Saharan Africa as in the rest of the world.
Limitations
The present study is an analysis of the patients enrolled in the
THESUS-HF study and as such shares certain limitations with the ori-
ginal cohort. The majority of the patients were recruited in a limited
numberofhospitals mainly in Nigeria,Uganda, andSouthAfrica.Most
importantly loss to follow-up and missing laboratory data and clinical
signs assessments were higher than in studies conducted in other
regions. Loss to follow-up is common in the population studied
due to a number of factors such as working opportunities if still
well (migrant workers), or need to be taken care of if not well.
Some tests are not performed as routinely in these institutions as
in institutions participating in other studies. Secondly, this registry
has been performed in selected centres and may represent only
AHF patients seen in specialized centres. Thirdly, HIV infection has
emerged as an important factor that predicts outcome in patients
with AHF in sub-Saharan Africa. Future studies should aim not only
to ensure testing of cases for heart failure, but also explore the con-
tribution of degree of immunosuppression (by CD4+ T cell count
testing), and the impact of anti-retroviral therapy. Finally, a larger
sample size with significant numbers of participants at each site will
be needed to provide valid comparisons between patients from
various countries in Africa. The small size of the database obviated
a split-sample approach to model validation; validation in another
sub-Saharan African cohort would provide greater confidence in
the findings.
Conclusions
Despite being one of the most common causes for hospital admis-
sions both globally and in sub-Saharan Africa, our knowledge of the
pathophysiologyof AHF is limited. In the present study, the predictive
models for60-day re-admission ordeathand 180-day mortality are of
the modest predictive value suggesting that some of the factors con-
tributing to the morbidity and mortality in AHF are unknown. For the
most part, the main predictors for these adverse outcomes are
similar in sub-Saharan Africa as in the rest of the world although
with some notable exceptions such as the association of the HIV
status with mortality and lack of prediction by sodium on both re-
admission and deaths.
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